Hemostasis, bleeding and thrombosis in liver disease

Area of Science:

• Hepatology
• Hematology
• Thrombosis Research

Background:

• Cirrhosis in chronic liver disease patients presents a dual risk of thrombosis and bleeding.
• This hemostatic imbalance stems from a complex interplay of procoagulant and anticoagulant dysregulation.
• The precise mechanisms underlying this imbalance remain incompletely understood.

Purpose of the Study:

• To provide an updated review of the pathophysiology of altered hemostasis and thrombophilia in cirrhosis.
• To discuss recent advancements in understanding portal vein thrombosis (PVT) and venous thromboembolism (VTE) in cirrhosis.
• To explore emerging prophylactic interventions and current treatment strategies for thrombosis in cirrhosis.

Main Methods:

• Literature review of pathophysiology and clinical studies.
• Analysis of proposed mechanisms including decreased synthesis of clotting factors and altered purinergic signaling.
• Examination of recent research on thrombotic events (PVT, VTE) and their management.

Main Results:

• Cirrhosis leads to decreased synthetic function and reduced natural anticoagulants.
• Potential contributing factors include decreased platelet production, hypersplenism, and altered clotting factor synthesis.
• Thrombotic events like PVT and VTE are significant causes of morbidity and mortality in cirrhosis.

Conclusions:

• The hemostatic system in cirrhosis is in a dynamic state of disequilibrium.
• Evolving understanding necessitates updated treatment recommendations for thrombosis and bleeding.
• New prophylactic and therapeutic strategies are being developed to manage thrombotic risks while mitigating hemorrhage.